Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

Por Vincenti, F., Blancho, G., Durrbach, A., Grannas, G., Grinyó, J., Meier‐Kriesche, H.‐U., Polinsky, M., Yang, L., Larsen, C. P.
Publicado no Am J Transplant (2017)

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

Por Florman, S., Becker, T., Bresnahan, B., Chevaile‐Ramos, A., Carvalho, D., Grannas, G., Muehlbacher, F., O'Connell, P. J., Meier‐Kriesche, H. U., Larsen, C. P.
Publicado no Am J Transplant (2016)

Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

Por Durrbach, A., Pestana, J. M., Florman, S., del Carmen Rial, M., Rostaing, L., Kuypers, D., Matas, A., Wekerle, T., Polinsky, M., Meier‐Kriesche, H. U., Munier, S., Grinyó, J. M.
Publicado no Am J Transplant (2016)